Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod plus meglumine antimoniate for cutaneous leishmaniasis
IRCT138706111166N1Phase 3Completed
- Sponsor
- WHO Regional Office for the Eastern Mediterranean
- Start
- Aug 2004
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of imiquimod, meglumine antimoniate in cutaneous leishmaniasis (CL), sponsored by WHO Regional Office for the Eastern Mediterranean. Started Aug 2004; status: completed.
02
Drugs
imiquimodmeglumine antimoniate
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on IRCT138706111166N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT138706111166N1.